Phosphodiesterase-5 Expression and Function in the Lower Urinary Tract: A Critical Review - 25/02/13
, Maarten Albersen b, Zhongcheng Xin c, Mikio Namiki d, Dieter Muller e, Tom F. Lue a
Reprint requests: Ching-Shwun Lin, M.D., Department of Urology, School of Medicine, University of California, San Francisco, CA 94143-0738.Abstract |
Both clinical and preclinical studies have mostly shown beneficial effects for Phosphodiesterase-5 (PDE-5) inhibitors in the treatment of lower urinary tract symptoms. Molecular studies have consistently shown abundant PDE-5 expression in bladder smooth muscle. Data concerning urethral PDE-5 expression have been surprising because striated muscle was not only positively identified, but also found to express more PDE-5 than the smooth muscle. In the prostate, highly variable results have been obtained. For PDE-5 expression, the data have ranged from extremely low to highly abundant. PDE-5 has been found in the glandular epithelium, vascular smooth muscle, endothelium, and fibromuscular stroma.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure: The authors declare that they have no relevant financial interests. |
|
| Funding Support: This work was supported by the National Institutes of Health (grants DK045370, DK64538, and DK069655). |
Vol 81 - N° 3
P. 480-487 - mars 2013 Retour au numéro
Article précédent
- Challenges Facing Academic Urology Training Programs: An Impending Crisis
- Chris M. Gonzalez, Patrick McKenna
- Grand Rounds: Müllerianosis of the Urinary Bladder in a Postmenopausal Woman
- Stephen McSorley, Agata Kochman, John DeSouza
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?